Phase 2 N=12 Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome
Metabolic Syndrome
Primary: Change in Hepatic Lipogenesis — 5.6 abs percent change fasting lipogenesis
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=41 Fatty Acid Oxidation Defects and Insulin Sensitivity
Very Long-chain Acyl-CoA Dehydrogenase Deficiency · Trifunctional Protein Deficiency · Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency
Primary: Glucose Disposal Rate (Rd)- the Rate of Glucose Infusion to Maintain Euglycemia During Steady State Insulin Infusion in mg/Min — 709; 429; 842; 497 mg/min — p=0.136
N/A N=17 Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome
HIV Lipodystrophy
Primary: Rate of Total Lipolysis — 0.649; 0.767 mmol FFA/kg/h
N/A N=106 Lipid Metabolism in Gestational Diabetes
Gestational Diabetes · Hyperlipidemia
Primary: Cholesterol — 204; 201 mg/dl
N/A N=4 Metabolomic Analysis of Hepatic Insulin Resistance
Type 2 Diabetes · Obesity
Primary: Insulin Sensitivity — 8 m value — p=<0.05
Phase 2 N=10 Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients
Familial Partial Lipodystrophy
Primary: Change in the Liver Triglycerides (TG). — 13.2; 6.4; 12.3; 10.6 percentage of liver triglycerides
Phase 2 N=5 Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension
Lipodystrophy
Primary: Change in Log 10 Fasting Triglycerides. — 0.1; -0.2 log 10 mg/dl
N/A N=30 Effect of Endoplasmic Reticulum Stress on Metabolic Function
Insulin Resistance · Diabetes · Obesity
Primary: Body Composition — 39; 39; 37; 39 percentage
Phase 2 N=2 Orlistat for the Treatment of Type I Hyperlipoproteinemia
Hyperlipoproteinemia Type I · Hypertriglyceridemia
Primary: Fasting Serum Triglycerides — 705; 1827; 1511; 1007 mg/dL
N/A N=70 Lipid Biomarkers for Diabetic Heart Disease
Type II Diabetes Mellitus · Diabetes Complications
Primary: Change in Cardiac Diastolic Function as Measured by E' (cm/s) — -0.02; 0.55 cm/s — p=0.07
Phase 2 N=32 Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder
Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency · Carnitine Palmitoyltransferase 2 (CPT2) Deficiency · Mitochondrial Trifunctional Protein (TFP) Deficiency
Primary: Energy Expenditure — -73; 107 kcal/day
Phase 2 N=13 High Protein Diet in Patients With Long-chain Fatty Acid Oxidation Disorders
Very Long-chain Acyl-CoA Dehydrogenase Deficiency · Trifunctional Protein Deficiency · Carnitine Palmitoyltransferase 2 Deficiency
Primary: Energy Expenditure — 2045; 2343 kcal
Phase 2 N=12 Blood Lipopolysaccharide (LPS) Rifaximin Study
Obese · Insulin Resistance · Metabolic Syndrome
Primary: Circulating LPS — 2.44; 1.86; 13.66; 10.00 EU/mL — p=>0.05
Phase 4 N=97 Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome
Metabolic Syndrome
Primary: Basal HDL-cholesterol Level — 39.5 mg/dL
N/A N=177 Diabetes and Lipid Accumulationand Heart Transplant
Diabetes Mellitus · Heart Failure
Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies
Phase 3 N=8 The Impact of Free Fatty Acid (FFA-) Suppression on Myocardial Lipids and Function in Patients With Type 2 Diabetes
Type 2 Diabetes
Primary: MYCL — 0.54; 0.44; 0.35; 0.36 percentage of water signal
N/A N=26 Fatty Acid Oxidation Disorders & Body Weight Regulation Grant
Trifunctional Protein Deficiency
Primary: An Outcome of This Study is the Difference in Percent Body Fat (%BF) Between Subjects With a Long-chain Fatty Acid Oxidation Disorder and Normal Controls. — 31.8; 27.2…
N/A N=90 PERIODONTAL DISEASE AND HYPERLIPIDEMIA
Hyperlipidemia, Periodontitis, Gingivitis
Primary: Gingival Crevicular Fluid Level of Malondialdehyde (MDA) as a Marker of Lipid Oxidation. — 144.09; 298.52; 802.09; 139.50 pg/ml
Phase 2 N=59 LIPIDS-P Trial Phase I/II Trial
Sepsis, Severe · Septic Shock
Primary: Phase II - Primary Outcome - Change in Total Cholesterol (48 Hours - Enrollment) — 9; -10; 4; 2 mg/dL
Phase 3 N=1,143 Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)
Hypercholesterolemia · Metabolic Syndrome
Primary: Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 6 — -36.5; -49.6; -39.4; -53.9 Percent Change — p=<0.001
Phase 2 N=5 Study of Gemcabene in Adults With FPLD
Familial Partial Lipodystrophy · Hypertriglyceridemia · Fatty Liver
Primary: Change in Fasting Serum Triglyceride (at 12 Weeks) — -0.44; -20.27 percent change — p=0.517
Phase 4 N=23 The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis
Type 2 Diabetes
Primary: Change in Liver Fat Content — 14.8; 16.1; 10.7; 13.9 fat % — p=0.001
N/A N=40 Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly
Acromegaly
Primary: Change in Liver Fat — 0.03 Lipid/water ratio
Phase 3 N=40 The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome
Metabolic Syndrome
Primary: Flow Mediated Vasodilation — 9.5; 10.8; 10.5; 10.9 percentage of vasodilation
Phase 2 N=405 Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome
Metabolic Syndrome
Primary: Blood Glucose Level — 6.05; 6.43; 4.58; 14.5 mmole/L
Phase 2 N=18 Cholic Acid for Hepatic Steatosis in Lipodystrophy
Hepatic Steatosis
Primary: Hepatic Triglyceride (%) — 15.9; 14.8 Fat/Fat+Water (%) — p=0.42
Phase 4 N=36 Effects of Metformin on Hepatic FFA Metabolism
Type 2 Diabetes · Dyslipidemia
Primary: Hepatic Fatty Acid Oxidation — 0.052; 0.045; 0.042 micromol/ml/min
N/A N=78 Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM
Diabetes Mellitus, Type II
Primary: Percent Change in Plasma Triglycerides — -2.0; 16.0; -5.0; -5.0 percent change
Phase 2 N=40 Implications for Treatment of the Metabolic Syndrome
Metabolic Syndrome
Primary: Muscle Microvascular Function — 3.7; 4.0 10^3 mL*min^-1*100ml^-1*mmHg^-1
N/A N=27 Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome
Metabolic Syndrome
Primary: Sarcoplasmic Reticulum Composition — 2.0; 2.2 PC:PE ratio